Advertisement
Corrigendum|Articles in Press

Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]

Open AccessPublished:February 27, 2023DOI:https://doi.org/10.1016/j.ejca.2023.02.004
Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]
Previous ArticleManagement of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Next ArticleCT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
      The authors regret that the acknowledgements section of the published paper was incomplete and should include the following statement:
      Raquel Vivet-Noguer was supported by the Institut Curie 3-i PhD Program under Marie Skłodowska-Curie Grant Agreement No 666003.
      The authors would like to apologise for any inconvenience caused.

      Article info

      Publication history

      Published online: February 27, 2023

      Publication stage

      In Press Corrected Proof

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2023.02.004

      Copyright

      © 2023 The Author(s). Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX